SK6622000A3 - Skin penetration enhancing components - Google Patents

Skin penetration enhancing components Download PDF

Info

Publication number: SK6622000A3
Authority: SK; Slovakia
Prior art keywords: formulation; macrocyclic lactone; derivative; macrolide; immunosuppressive macrolide
Prior art date: 1997-11-07

Application number

SK662-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Anthony David Ormerod

Arthur Winfield

Original Assignee

Univ Aberdeen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-07

Filing date

1998-11-05

Publication date

2001-01-18

1998-11-05 Application filed by Univ Aberdeen filed Critical Univ Aberdeen

2001-01-18 Publication of SK6622000A3 publication Critical patent/SK6622000A3/sk

Links

230000035515 penetration Effects 0.000 title description 6
230000002708 enhancing effect Effects 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 48
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 42
229960002930 sirolimus Drugs 0.000 claims abstract description 42
239000003120 macrolide antibiotic agent Substances 0.000 claims abstract description 36
230000001506 immunosuppresive effect Effects 0.000 claims abstract description 30
230000003115 biocidal effect Effects 0.000 claims abstract description 28
150000002596 lactones Chemical class 0.000 claims abstract description 27
229940002612 prodrug Drugs 0.000 claims abstract description 12
239000000651 prodrug Substances 0.000 claims abstract description 12
230000009885 systemic effect Effects 0.000 claims abstract description 9
230000001225 therapeutic effect Effects 0.000 claims abstract description 6
239000012049 topical pharmaceutical composition Substances 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 44
238000009472 formulation Methods 0.000 claims description 40
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 29
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 20
239000002904 solvent Substances 0.000 claims description 14
201000004681 Psoriasis Diseases 0.000 claims description 13
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 10
235000019445 benzyl alcohol Nutrition 0.000 claims description 9
230000000699 topical effect Effects 0.000 claims description 9
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
208000010668 atopic eczema Diseases 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
201000004624 Dermatitis Diseases 0.000 claims description 5
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 5
239000002562 thickening agent Substances 0.000 claims description 5
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
239000005642 Oleic acid Substances 0.000 claims description 4
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 4
-1 fatty acid ester Chemical class 0.000 claims description 4
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 claims description 4
206010040872 skin infection Diseases 0.000 claims description 4
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
208000002874 Acne Vulgaris Diseases 0.000 claims description 3
206010000496 acne Diseases 0.000 claims description 3
229960004099 azithromycin Drugs 0.000 claims description 3
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims description 3
229960003276 erythromycin Drugs 0.000 claims description 3
239000012188 paraffin wax Substances 0.000 claims description 3
239000002243 precursor Substances 0.000 claims description 3
201000004384 Alopecia Diseases 0.000 claims description 2
208000006311 Pyoderma Diseases 0.000 claims description 2
206010047642 Vitiligo Diseases 0.000 claims description 2
231100000360 alopecia Toxicity 0.000 claims description 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 2
150000001555 benzenes Chemical class 0.000 claims description 2
229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
229960002626 clarithromycin Drugs 0.000 claims description 2
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
238000002054 transplantation Methods 0.000 claims description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
150000001735 carboxylic acids Chemical class 0.000 claims 1
239000004203 carnauba wax Substances 0.000 claims 1
235000013869 carnauba wax Nutrition 0.000 claims 1
229960000541 cetyl alcohol Drugs 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
210000004877 mucosa Anatomy 0.000 claims 1
239000000344 soap Substances 0.000 claims 1
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
210000003491 skin Anatomy 0.000 description 10
210000000434 stratum corneum Anatomy 0.000 description 10
230000000694 effects Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
238000001574 biopsy Methods 0.000 description 6
239000003018 immunosuppressive agent Substances 0.000 description 6
230000003902 lesion Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
210000002615 epidermis Anatomy 0.000 description 5
229940125721 immunosuppressive agent Drugs 0.000 description 5
238000005259 measurement Methods 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
235000021313 oleic acid Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
210000004761 scalp Anatomy 0.000 description 4
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
208000017520 skin disease Diseases 0.000 description 3
239000000126 substance Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000004907 flux Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000010410 layer Substances 0.000 description 2
150000002632 lipids Chemical group 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
229940041033 macrolides Drugs 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
230000037368 penetrate the skin Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
230000004707 G1/S transition Effects 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000000521 Immunophilins Human genes 0.000 description 1
108010016648 Immunophilins Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
239000004902 Softening Agent Substances 0.000 description 1
241000187391 Streptomyces hygroscopicus Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 1
AKGGYBADQZYZPD-UHFFFAOYSA-N benzyl acetone Natural products CC(=O)CCC1=CC=CC=C1 AKGGYBADQZYZPD-UHFFFAOYSA-N 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000032823 cell division Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000013554 lipid monolayer Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cosmetics (AREA)

SK662-2000A 1997-11-07 1998-11-05 Skin penetration enhancing components SK6622000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9723669.9A GB9723669D0 (en)	1997-11-07	1997-11-07	Skin penetration enhancing components
PCT/GB1998/003317 WO1999024036A1 (fr)	1997-11-07	1998-11-05	Composants ameliorant la penetration dans la peau

Publications (1)

Publication Number	Publication Date
SK6622000A3 true SK6622000A3 (en)	2001-01-18

Family

ID=10821813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK662-2000A SK6622000A3 (en)	1997-11-07	1998-11-05	Skin penetration enhancing components

Country Status (33)

Country	Link
US (2)	US6958153B1 (fr)
EP (2)	EP1028727B1 (fr)
JP (1)	JP2001522801A (fr)
KR (1)	KR20010031741A (fr)
CN (1)	CN1115148C (fr)
AR (1)	AR014011A1 (fr)
AT (1)	ATE332134T1 (fr)
AU (1)	AU759326B2 (fr)
BG (1)	BG104370A (fr)
BR (1)	BR9815264A (fr)
CA (1)	CA2309159C (fr)
CY (1)	CY1105243T1 (fr)
DE (1)	DE69835163T2 (fr)
DK (1)	DK1028727T3 (fr)
EA (1)	EA003616B1 (fr)
EE (1)	EE04390B1 (fr)
ES (1)	ES2268795T3 (fr)
GB (1)	GB9723669D0 (fr)
GE (2)	GEP20043171B (fr)
HR (1)	HRP20000233A2 (fr)
HU (1)	HUP0003675A3 (fr)
ID (1)	ID24662A (fr)
IL (1)	IL135978A0 (fr)
NO (1)	NO20002078L (fr)
NZ (3)	NZ530752A (fr)
PL (1)	PL340710A1 (fr)
PT (1)	PT1028727E (fr)
SK (1)	SK6622000A3 (fr)
TR (1)	TR200001238T2 (fr)
TW (1)	TW557218B (fr)
UA (1)	UA73274C2 (fr)
WO (1)	WO1999024036A1 (fr)
ZA (1)	ZA9810111B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9826656D0 (en)	1998-12-03	1999-01-27	Novartis Ag	Organic compounds
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1133987A1 (fr) *	2000-03-09	2001-09-19	Ian Whitcroft	Traitement de dermatoses inflammatoires avec une combinaison d'erythromycine ou clarithromycine, métronidazole et un inhibiteur des pompes à hydrogène
EP1263445A1 (fr) *	2000-03-09	2002-12-11	Ian Whitcroft	Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal
ATE427948T1 (de) *	2001-04-24	2009-04-15	Purdue Research Foundation	Folat-mimetika und deren folatrezeptorbindende konjugate
HRP20010301A2 (en) *	2001-04-27	2001-12-31	Pliva D D	New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
ATE429947T1 (de)	2001-08-29	2009-05-15	Pharmakodex Ltd	Vorrichtung zur topischen verabreichung
CN1617709A (zh) *	2001-12-13	2005-05-18	兰贝克赛实验室有限公司	克拉霉素的稳定局部制剂
US7910594B2 (en) *	2002-05-15	2011-03-22	Endocyte, Inc.	Vitamin-mitomycin conjugates
EP2517730A3 (fr)	2003-01-27	2013-01-02	Endocyte, Inc.	Conjugués d'administration de médicaments à liaison au récepteur de vitamines
WO2004071398A2 (fr) *	2003-02-17	2004-08-26	Cipla Ltd	Composition pharmaceutique
AR043504A1 (es) *	2003-03-17	2005-08-03	Novartis Ag	Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307869D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
GB0307865D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
US20050079228A1 (en) *	2003-05-30	2005-04-14	Ashish Jaiswal	Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
US20070154966A1 (en) *	2003-12-29	2007-07-05	Ronit Sagi-Eisenberg	Assay for the detection of rapamycin and rapamycin analogs
WO2006012527A1 (fr)	2004-07-23	2006-02-02	Endocyte, Inc.	Groupes de liaison bivalents et conjugués de ceux-ci
CA2580286A1 (fr) *	2004-09-16	2006-03-23	Bayer Healthcare Ag	Formulations s'appliquant par voie cutanee pour traiter des maladies de la peau chez des animaux
CN101175474B (zh) *	2005-03-10	2011-09-07	3M创新有限公司	降低微生物污染的方法
JP5289935B2 (ja) *	2005-03-16	2013-09-11	エンドサイト，インコーポレイテッド	プテロイン酸およびその結合体の合成と精製
EP1948240A2 (fr) *	2005-08-19	2008-07-30	Endocyte, Inc.	Conjugues de ligand d'alcaloides vinca, analogues et derives
CN103893779A (zh)	2005-08-19	2014-07-02	恩多塞特公司	多药物配体缀合物
US7704959B2 (en) *	2006-10-03	2010-04-27	Dow Pharmaceutical Sciences	Azithromycin for the treatment of nodular acne
WO2008063563A2 (fr)	2006-11-16	2008-05-29	Transderm, Inc.	Méthodes de traitement de maladies liées à l'hyperprolifération de la kératine au moyen d'inhibiteurs de mtor
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
WO2008101231A2 (fr)	2007-02-16	2008-08-21	Endocyte, Inc.	Procédés et compositions de traitement et de diagnostic d'une maladie rénale
EP2489372A3 (fr) *	2007-03-14	2013-01-02	Endocyte, Inc.	Conjugués de tubulysines d'administration de médicament liés à un ligand de liaison
ES2732879T3 (es)	2007-06-25	2019-11-26	Endocyte Inc	Conjugados que contienen enlazantes espaciadores hidrófilos
US9877965B2 (en)	2007-06-25	2018-01-30	Endocyte, Inc.	Vitamin receptor drug delivery conjugates for treating inflammation
US7919250B2 (en)	2007-07-31	2011-04-05	New York University	Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
JP2011500835A (ja)	2007-10-25	2011-01-06	エンドサイト，インコーポレイテッド	チューブリシン類および調製プロセス
WO2010024898A2 (fr)	2008-08-29	2010-03-04	Lutonix, Inc.	Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet
US20100086581A1 (en) *	2008-10-07	2010-04-08	Ernest Bove	Method for purpura reduction and prevention
EP2308468A1 (fr) *	2009-10-08	2011-04-13	Novaliq GmbH	Nouvelle composition pharmaceutique comportant un médicament contre l'immunosuppression macrolide
US20110150856A1 (en)	2009-12-21	2011-06-23	Sarah Bacus	Compositions and methods for treatment of vitiligo
WO2011079154A1 (fr) *	2009-12-21	2011-06-30	Sarah Bacus	Compositions et méthodes de traitement du vitiligo
US20120022095A1 (en) *	2010-06-24	2012-01-26	Teng Joyce M C	Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
JP5652795B2 (ja) *	2011-01-31	2015-01-14	国立大学法人大阪大学	皮膚疾患を処置するための外用薬およびその製造方法
WO2012142145A1 (fr) *	2011-04-12	2012-10-18	Dow Pharmaceutical Sciences	Méthodes de traitement d'affections cutanées exhibant une télangiectasie
CN102552253A (zh) *	2012-01-17	2012-07-11	唯美度科技（北京）有限公司	一种祛痘用皮肤外用剂
US10080805B2 (en)	2012-02-24	2018-09-25	Purdue Research Foundation	Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en)	2012-03-29	2014-03-20	Endocyte, Inc.	Processes for preparing tubulysin derivatives and conjugates thereof
SG11201502896XA (en)	2012-10-16	2015-05-28	Endocyte Inc	Drug delivery conjugates containing unnatural amino acids and methods for using
DK2948134T3 (da) *	2013-01-24	2020-06-02	Palvella Therapeutics Inc	Sammensætninger til transdermal indgivelse af mtor-inhibitorer
HUP1400075A2 (hu)	2014-02-14	2015-08-28	Druggability Technologies Ip Holdco Jersey Ltd	Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
EP3162380A1 (fr) *	2014-06-26	2017-05-03	Osaka University	Agent anti-transpirant
AU2016325446B2 (en)	2015-09-24	2021-05-13	Drexel University	Novel compositions and methods for treating or preventing dermal disorders
FR3050206B1 (fr)	2016-04-15	2018-05-11	Engie	Dispositif et procede d'hydrogenation pour produire du methanol et dispositif et procede de cogeneration de methanol et de methane de synthese
AU2017311491A1 (en)	2016-08-10	2019-02-07	The Board Of Regents Of The University Of Texas System	Topical rapamycin therapy
EP3565520A4 (fr) *	2017-01-06	2020-08-19	Palvella Therapeutics, Inc.	Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
JP2021530463A (ja)	2018-07-02	2021-11-11	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物および使用方法
CA3131232A1 (fr)	2019-02-20	2020-08-27	AI Therapeutics, Inc.	Formulations topiques de rapamycine et leur utilisation dans le traitement d'angiofibromes faciaux et d'autres troubles cutanes
CN116056687A (zh)	2020-03-02	2023-05-02	上海奥科达医药科技股份有限公司	含有mtor抑制剂的外用制剂
FR3112537B1 (fr)	2020-07-14	2023-03-31	Engie	Dispositif et procédé de production hybride de dihydrogène de synthèse et/ou de méthane de synthèse
AU2020277132B1 (en) *	2020-11-24	2021-11-04	Aft Pharmaceuticals Limited	A Rapamycin Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US31769A (en) *		1861-03-26		Water-elevator
US3376646A (en) *	1967-03-30	1968-04-09	Herman E. Radke	Template tracer
US4335115A (en)	1976-11-01	1982-06-15	The Procter & Gamble Company	Anti-acne composition
US4954487A (en) *	1979-01-08	1990-09-04	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions
US4299826A (en) *	1979-10-12	1981-11-10	The Procter & Gamble Company	Anti-acne composition
CA1165240A (fr) *	1980-07-09	1984-04-10	The Procter & Gamble Company	Composes pharmaceutiques a usage topique
AU618517B2 (en) *	1986-12-23	1992-01-02	Eugene J. Van Scott	Additives enhancing topical actions of therapeutic agents
US5023085A (en) *	1989-11-29	1991-06-11	Pfizer Inc.	Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
CA2033725C (fr) *	1990-01-24	2001-05-29	Folker Pittrof	Compositions pharmaceutiques et cosmetiques
EP0474126B1 (fr) *	1990-09-04	1997-03-19	Fujisawa Pharmaceutical Co., Ltd.	Onguents à base de composés tricycliques
ES2136105T3 (es)	1992-08-04	1999-11-16	Rhone Poulenc Rorer Gmbh	Preparacion farmaceutica y/o cosmetica.
US5462746A (en) *	1992-11-02	1995-10-31	Lts Lohmann Therapie-Systeme Gmbh & Co. Kg	Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FI90649C (fi)	1993-02-01	1994-03-10	Pauli Groenberg	Menetelmä hevosen satulan sovittamiseksi hevosen selkään
CH686761A5 (de) *	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
JPH06345646A (ja) *	1993-06-08	1994-12-20	Fujisawa Pharmaceut Co Ltd	ローション剤
JPH08133979A (ja) *	1994-09-16	1996-05-28	Sando Yakuhin Kk	局所適用薬剤組成物
NZ331824A (en) *	1994-10-26	2000-01-28	Novartis Ag	use of an unsaturated fatty alcohol to stabilise a macrolide in a pharmaceutical composition
US5648389A (en) *	1995-10-27	1997-07-15	Medicis Pharmaceutical, Inc.	Compositions for the treatment of dermatological disorders and methods for their use

1997
- 1997-11-07 GB GBGB9723669.9A patent/GB9723669D0/en not_active Ceased
1998
- 1998-05-11 UA UA2000063310A patent/UA73274C2/uk unknown
- 1998-10-23 TW TW087117554A patent/TW557218B/zh not_active IP Right Cessation
- 1998-11-04 AR ARP980105560A patent/AR014011A1/es unknown
- 1998-11-05 GE GEAP19986193A patent/GEP20043171B/en unknown
- 1998-11-05 CN CN98810780A patent/CN1115148C/zh not_active Expired - Fee Related
- 1998-11-05 EA EA200000461A patent/EA003616B1/ru not_active IP Right Cessation
- 1998-11-05 US US09/530,375 patent/US6958153B1/en not_active Expired - Fee Related
- 1998-11-05 ZA ZA9810111A patent/ZA9810111B/xx unknown
- 1998-11-05 TR TR2000/01238T patent/TR200001238T2/xx unknown
- 1998-11-05 NZ NZ530752A patent/NZ530752A/en unknown
- 1998-11-05 DK DK98952860T patent/DK1028727T3/da active
- 1998-11-05 SK SK662-2000A patent/SK6622000A3/sk unknown
- 1998-11-05 AU AU10408/99A patent/AU759326B2/en not_active Ceased
- 1998-11-05 IL IL13597898A patent/IL135978A0/xx unknown
- 1998-11-05 EP EP98952860A patent/EP1028727B1/fr not_active Expired - Lifetime
- 1998-11-05 EE EEP200000279A patent/EE04390B1/xx not_active IP Right Cessation
- 1998-11-05 WO PCT/GB1998/003317 patent/WO1999024036A1/fr active IP Right Grant
- 1998-11-05 JP JP2000520128A patent/JP2001522801A/ja not_active Withdrawn
- 1998-11-05 DE DE69835163T patent/DE69835163T2/de not_active Expired - Fee Related
- 1998-11-05 ES ES98952860T patent/ES2268795T3/es not_active Expired - Lifetime
- 1998-11-05 GE GEAP19985335A patent/GEP20032884B/en unknown
- 1998-11-05 EP EP05007320A patent/EP1632231A3/fr not_active Withdrawn
- 1998-11-05 KR KR1020007004806A patent/KR20010031741A/ko not_active Ceased
- 1998-11-05 HU HU0003675A patent/HUP0003675A3/hu unknown
- 1998-11-05 PL PL98340710A patent/PL340710A1/xx unknown
- 1998-11-05 ID IDW20000846A patent/ID24662A/id unknown
- 1998-11-05 BR BR9815264-5A patent/BR9815264A/pt active Search and Examination
- 1998-11-05 AT AT98952860T patent/ATE332134T1/de not_active IP Right Cessation
- 1998-11-05 NZ NZ520449A patent/NZ520449A/en unknown
- 1998-11-05 CA CA002309159A patent/CA2309159C/fr not_active Expired - Fee Related
- 1998-11-05 NZ NZ504076A patent/NZ504076A/xx unknown
- 1998-11-05 PT PT98952860T patent/PT1028727E/pt unknown
2000
- 2000-04-19 NO NO20002078A patent/NO20002078L/no unknown
- 2000-04-20 HR HR20000233A patent/HRP20000233A2/xx not_active Application Discontinuation
- 2000-04-24 BG BG104370A patent/BG104370A/xx unknown
2005
- 2005-06-16 US US11/153,318 patent/US20050239724A1/en not_active Abandoned
2006
- 2006-09-20 CY CY20061101341T patent/CY1105243T1/el unknown

Also Published As

Publication number	Publication date
AU1040899A (en)	1999-05-31
HRP20000233A2 (en)	2001-02-28
BG104370A (en)	2000-12-29
UA73274C2 (en)	2005-07-15
GB9723669D0 (en)	1998-01-07
NZ504076A (en)	2002-12-20
AR014011A1 (es)	2001-01-31
EA200000461A1 (ru)	2000-10-30
ES2268795T3 (es)	2007-03-16
HUP0003675A2 (hu)	2001-04-28
KR20010031741A (ko)	2001-04-16
PL340710A1 (en)	2001-02-26
ATE332134T1 (de)	2006-07-15
CN1115148C (zh)	2003-07-23
CA2309159C (fr)	2009-03-17
TR200001238T2 (tr)	2001-01-22
AU759326B2 (en)	2003-04-10
TW557218B (en)	2003-10-11
NO20002078D0 (no)	2000-04-19
EP1632231A2 (fr)	2006-03-08
GEP20043171B (en)	2004-02-25
EP1028727A1 (fr)	2000-08-23
EP1632231A3 (fr)	2008-01-23
PT1028727E (pt)	2006-11-30
JP2001522801A (ja)	2001-11-20
CN1278173A (zh)	2000-12-27
DE69835163D1 (de)	2006-08-17
US6958153B1 (en)	2005-10-25
DE69835163T2 (de)	2007-05-31
DK1028727T3 (da)	2006-10-23
EP1028727B1 (fr)	2006-07-05
NO20002078L (no)	2000-07-06
CA2309159A1 (fr)	1999-05-20
IL135978A0 (en)	2001-05-20
NZ530752A (en)	2005-05-27
ID24662A (id)	2000-07-27
HUP0003675A3 (en)	2001-05-28
GEP20032884B (en)	2003-02-25
BR9815264A (pt)	2001-08-14
CY1105243T1 (el)	2010-03-03
EE200000279A (et)	2001-10-15
EA003616B1 (ru)	2003-08-28
US20050239724A1 (en)	2005-10-27
WO1999024036A1 (fr)	1999-05-20
NZ520449A (en)	2004-04-30
EE04390B1 (et)	2004-12-15
ZA9810111B (en)	1999-05-07

Publication	Publication Date	Title
SK6622000A3 (en)	2001-01-18	Skin penetration enhancing components
US6180666B1 (en)	2001-01-30	Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
DE69526428T2 (de)	2002-10-10	Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
CA2301017C (fr)	2008-12-09	Utilisation de gallate de propyle pour augmenter la biodisponibilite de produits pharmaceutiques administres par voie orale
Gatti et al.	1993	Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS
Hermann et al.	1988	Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study
Birkett et al.	1990	Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing
Lakritz et al.	2000	Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals
US20060089406A1 (en)	2006-04-27	Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
Dasgupta	2016	Monitoring free mycophenolic acid concentration: Is there any clinical advantage?
Yogo et al.	2007	Effects of motilin and mitemcinal (GM-611) on gastrointestinal contractile activity in rhesus monkeys in vivo and in vitro
AU2003211175B2 (en)	2006-06-15	Skin penetration enhancing components
Gretler et al.	2020	Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses
MXPA00004340A (en)	2002-06-05	Skin penetration enhancing components
AU2006213973A1 (en)	2006-10-05	Skin penetration enhancing components
US20080132534A1 (en)	2008-06-05	Pharmaceutical composition comprising a macrolide immunomodulator
CZ20001662A3 (cs)	2000-10-11	Prostředek pro místní podání
Xu et al.	1997	Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action
Pérez et al.	2009	Transplacental exchange of moxidectin after maternal or fetal intravenous administration in sheep
BG66299B1 (bg)	2013-03-29	Използване на противогъбични средства
Parsons et al.	1976	Effect of recumbency on erythromycin absorption
Bohlen	1993	Effects of ivermectin on antipyrine and erythromycin disposition in cattle
CA2519096A1 (fr)	2004-10-14	Combinaison d'un immunomodulateur de lymphocyte t macrolide et d'un calciferol destinee au traitement de maladies de la peau ou d'une maladie intestinale inflammatoire
Ghosh	2001	REVIEW OF CURRENT LITERATURE